Key facts
- It has raised $20.0M across 1 recorded rounds; the latest was Early Stage VC ($5.9M) in Jan 2024.
- Notable investors include Google for Startups, Labcorp Venture Fund, Sonen Capital, Covance, Endeavor Argentina — 12 tracked in total.
- Biomakers has filed 2 Form Ds with the SEC since 2024, most recently Feb 2025 ($2.4M sold to 5 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Biomakers
Funding rounds
1 roundsAbout Biomakers
Operator of a precision medicine center intended to develop personalized drugs. The company leverages genetic sequencing and in-depth bioinformatics analysis to provide differential genetic counseling services for all available trials and transforms genomic and molecular information into therapeutic analysis, enabling healthcare professionals to make treatment decisions based on scientific data available for their patients.
- Sector
- Healthcare
- HQ
- Buenos Aires, Argentina
- Founded
- 2014
- Employees
- 77
- Website
- biomakers.io/
- Ownership
- Privately Held (backing)
Biomakers doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Biomakers shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Biomakers in its N-PORT filings yet. We sweep new filings monthly.